Baba Kalyani’s Association with Hikal Ltd: Investment and Shareholding

The connection between Baba Kalyani and Hikal Ltd is rooted in the company’s early development, historical board representation, financial support and the shareholding interests of companies associated with the Kalyani family. Hikal Limited is an Indian pharmaceutical, crop protection and specialty chemicals company that serves customers in domestic and international markets.

Baba Kalyani, formally known as Babasaheb Neelkanth Kalyani, is widely recognised for his leadership in Indian manufacturing through Bharat Forge. His association with Hikal dates back to the company’s formative years, when financial support from a Kalyani-linked entity helped establish its first manufacturing facility.

Baba Kalyani’s Historical Association With Hikal Ltd

Baba Kalyani has been associated with Hikal since 1989, when the company was a wholly owned subsidiary of Surajmukhi, which was then a subsidiary of Kalyani Steels Limited.

In a letter submitted to Hikal on 29 December 2023, Baba Kalyani stated that funding from Surajmukhi enabled Hikal to establish its first manufacturing facility and commence commercial production in 1992.

This historical contribution is an important part of Hikal’s corporate development. The financial support helped provide the foundation for the company’s manufacturing operations during its early years.

The relationship subsequently extended to board representation and the shareholding interests of companies connected with the Kalyani family. These historical links form part of the documented corporate background of Hikal Ltd.

Financial Contribution of Kalyani-Linked Companies to Hikal

The early development of Hikal involved financial support from Surajmukhi, a company within the Kalyani-linked corporate structure at the time. According to Baba Kalyani’s December 2023 letter, this funding helped establish Hikal’s first facility and supported the start of commercial production.

The contribution is significant because manufacturing businesses in pharmaceuticals and specialty chemicals require investment in facilities, equipment, production processes and quality systems before commercial operations can begin.

The establishment of its first facility provided Hikal with the initial manufacturing base from which it could develop its operations and serve customers.

It is important to distinguish this historical funding contribution from a direct personal investment by Baba Kalyani. The documented letter identifies Surajmukhi as the entity that provided the funding. It does not establish that the entire contribution was made from Baba Kalyani’s personal funds.

Baba Kalyani Hikal Ltd: Shareholding and Investment Interests

The shareholding relationship between the Kalyani family and Hikal has been an important part of the company’s corporate history.

Kalyani Investment Company Limited and BF Investment Limited are among the Kalyani-linked entities associated with Hikal’s shareholding structure. Business reporting ahead of Hikal’s September 2026 annual general meeting placed their combined holding at approximately 34.01%.

This combined figure refers to the holdings of the two companies, not necessarily to shares personally owned by Baba Kalyani. Corporate shareholdings and individual shareholdings must be assessed separately using official disclosures.

For the latest ownership position, Hikal’s published shareholding patterns and the relevant companies’ annual reports provide the appropriate reference points. These records help establish the number and percentage of shares held by each disclosed shareholder during a particular reporting period.

Shareholding interests can be relevant to shareholder voting, board appointments and corporate governance. However, ownership percentages alone do not establish operational control or the extent of an individual’s personal financial contribution to a company.

Baba Kalyani’s Role on the Hikal Ltd Board

Baba Kalyani served on Hikal’s board for approximately 31 years. His association with the board ended in December 2023 following a shareholder vote on his continuation as a non-executive, non-independent director.

In his resignation letter dated 29 December 2023, Kalyani referred to the shareholder voting outcome and his long association with the company. His departure marked the end of an extended period of board representation.

Hikal Ltd’s Business Development and Manufacturing Operations

Hikal operates across pharmaceuticals, crop protection and specialty chemicals. Its business includes pharmaceutical ingredients and intermediates, contract development and manufacturing services, research and development, and products for agricultural applications.

The company’s development since its early manufacturing years illustrates the importance of investment in production capabilities, technical expertise and customer relationships.

Hikal’s current business performance depends on several factors, including regulatory compliance, customer demand, operating efficiency, product development and international market conditions.

Conclusion

The relationship between Baba Kalyani and Hikal Ltd includes a documented historical contribution to the company’s early development, a long period of board representation and shareholding interests held through Kalyani-linked corporate entities.

Baba Kalyani’s December 2023 letter records that funding from Surajmukhi enabled Hikal to establish its first manufacturing facility and commence commercial production in 1992. Separately, the shareholding interests of Kalyani Investment Company and BF Investment form part of the company’s reported ownership structure.